Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients With MDR-TB After Successful Intensive-phase Treatment.

NCT02711735 is registered in ClinicalTrials.gov with Archivel Farma S.L. as lead sponsor.

NCT NCT02711735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02711735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients With MDR-TB After Successful Intensive-phase Treatment.
Lead sponsor
Archivel Farma S.L.
Phase
Phase 2
Overall status
Terminated
Start date
March 18, 2020
Completion date
September 9, 2020
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis, multidrug resistant